Home › Companies › KalVista Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and KalVista Pharmaceuticals, Inc.’s Form 8-K, filed October 2, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of October 1, 2025: 4 items on KalVista Pharmaceuticals, Inc.’s Form 8-K, filed October 2, 2025: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore KalVista Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are KalVista Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed October 2, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Benjamin L. Palleiko | 36,096,804 | 1,491,876 | 3,100 | -- | 3,882,274 | 96% | Not verified | — |
| Elect Director: Brian J.G. Pereira | 30,303,728 | 7,284,941 | 3,111 | -- | 3,882,274 | 81% | Not verified | — |
| 2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the eight-month transition period ending December 31, 2025 | 41,421,548 | 44,417 | 8,089 | -- | 0 | 99.8% | Not verified | — |
| 3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers | 33,600,808 | 3,985,860 | 5,112 | -- | 3,882,274 | 89% | Not verified | — |
Source: KalVista Pharmaceuticals, Inc., Form 8-K, filed with the SEC on October 2, 2025 — read the filing on EDGAR.
Each item below shows how the 165 asset managers that disclosed a KalVista Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: The election of two Class I directors to hold office until the earliest of our 2028 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: Benjamin L. Palleiko
KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Benjamin L. Palleiko”): 36,096,804 for, 1,491,876 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 7,651,957 for, 905,786 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 3,177,587 | 0 | 0 | 0 | For |
| Vanguard | 2,116,269 | 0 | 0 | 0 | For |
| BlackRock | 1,071,698 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 601,685 | 0 | 0 | Against |
| Principal | 1,691 | 286,670 | 0 | 0 | Against |
| Fidelity | 275,464 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 0 | 0 | 0 | For |
| Charles Schwab | 113,454 | 0 | 0 | 0 | For |
| Equitable | 95,008 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 78,858 | 0 | 0 | 0 | For |
| TIAA | 67,977 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,500 | 0 | 0 | 0 | For |
| Russell Investments | 52,939 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 50,205 | 0 | 0 | 0 | For |
| State Street | 41,676 | 0 | 0 | 0 | For |
| Northern Trust | 30,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 29,200 | 0 | 0 | 0 | For |
| ProShares | 19,863 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,236 | 0 | 0 | 0 | For |
| Global X | 19,029 | 0 | 0 | 0 | For |
| Dimensional | 0 | 17,431 | 0 | 0 | Against |
| John Hancock | 14,574 | 0 | 0 | 0 | For |
| Invesco | 14,068 | 0 | 0 | 0 | For |
| Pacific Life | 11,918 | 0 | 0 | 0 | For |
| Nationwide | 11,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 4 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: The election of two Class I directors to hold office until the earliest of our 2028 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: Brian J.G. Pereira
KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Brian J.G. Pereira”): 30,303,728 for, 7,284,941 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 7,136,671 for, 1,421,072 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 3,177,587 | 0 | 0 | 0 | For |
| Vanguard | 2,116,269 | 0 | 0 | 0 | For |
| BlackRock | 1,071,698 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 601,685 | 0 | 0 | Against |
| Principal | 0 | 288,361 | 0 | 0 | Against |
| Fidelity | 275,464 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 0 | 0 | 0 | For |
| Charles Schwab | 113,454 | 0 | 0 | 0 | For |
| Equitable | 68,398 | 26,610 | 0 | 0 | Mixed |
| CARILLON SERIES TRUST | 0 | 78,858 | 0 | 0 | Against |
| TIAA | 0 | 67,977 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 61,500 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 52,939 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 50,205 | 0 | 0 | Against |
| State Street | 67 | 41,609 | 0 | 0 | Against |
| Northern Trust | 0 | 30,794 | 0 | 0 | Against |
| Lincoln Financial | 0 | 29,200 | 0 | 0 | Against |
| ProShares | 0 | 19,863 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 19,236 | 0 | 0 | Against |
| Global X | 0 | 19,029 | 0 | 0 | Against |
| Dimensional | 0 | 17,431 | 0 | 0 | Against |
| John Hancock | 0 | 14,574 | 0 | 0 | Against |
| Invesco | 0 | 14,068 | 0 | 0 | Against |
| Pacific Life | 11,918 | 0 | 0 | 0 | For |
| Nationwide | 11,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 7 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.
KalVista Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers”): 33,600,808 for, 3,985,860 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 3,177,587 | 0 | 0 | Against |
| Vanguard | 2,116,269 | 0 | 0 | 0 | For |
| BlackRock | 1,071,698 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 601,685 | 0 | 0 | 0 | For |
| Principal | 288,361 | 0 | 0 | 0 | For |
| Fidelity | 275,464 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 0 | 0 | 0 | For |
| Charles Schwab | 113,454 | 0 | 0 | 0 | For |
| Equitable | 95,008 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 78,858 | 0 | 0 | 0 | For |
| TIAA | 67,977 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,500 | 0 | 0 | 0 | For |
| Russell Investments | 52,939 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 50,205 | 0 | 0 | 0 | For |
| State Street | 41,661 | 15 | 0 | 0 | For |
| Northern Trust | 30,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 29,200 | 0 | 0 | 0 | For |
| ProShares | 19,863 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,236 | 0 | 0 | 0 | For |
| Global X | 19,029 | 0 | 0 | 0 | For |
| Dimensional | 17,431 | 0 | 0 | 0 | For |
| John Hancock | 14,574 | 0 | 0 | 0 | For |
| Invesco | 0 | 14,068 | 0 | 0 | Against |
| Pacific Life | 11,918 | 0 | 0 | 0 | For |
| Nationwide | 11,431 | 0 | 0 | 0 | For |
Fund voting reports, all 42 managers: 5,362,342 for, 3,195,401 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | 6,728,985 | 0 | 0 | 0 | For |
| MONTANOVA CAPITAL, LLC | 4,768,712 | 0 | 0 | 0 | For |
| Capital Group | 0 | 3,177,587 | 0 | 0 | Against |
| Vestal Point Capital, LP | 1,296,235 | 0 | 0 | 0 | For |
| BlackRock | 1,230,624 | 20,039 | 0 | 0 | For |
| Octagon Capital Advisors LP | 1,068,496 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 951,112 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 888,355 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 505,438 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 444,731 | 0 | 0 | 0 | For |
| State Street | 423,973 | 105 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 353,425 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 340,145 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 316,095 | 0 | 0 | 0 | For |
| Northern Trust | 226,191 | 0 | 0 | 0 | For |
| NAN FUNG TRINITY (HK) Ltd | 154,522 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 149,507 | 0 | 0 | 0 | For |
| Charles Schwab | 113,531 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 113,171 | 0 | 0 | 0 | For |
| Vanguard | 102,782 | 0 | 0 | 0 | For |
| Goldman Sachs | 95,838 | 0 | 0 | 0 | For |
| Wellington | 90,852 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 82,383 | 0 | 0 | Against |
| Nuveen | 79,758 | 0 | 0 | 0 | For |
| NEXTBio Capital Management LP | 65,896 | 0 | 0 | 0 | For |
Institutional-manager reports, all 136 managers: 21,325,213 for, 3,371,722 against. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: THE RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF OUR BOARD, OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR EIGHT-MONTH TRANSITION PERIOD ENDING DECEMBER 31, 2025.
KalVista Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the eight-month transition period ending December 31, 2025”): 41,421,548 for, 44,417 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 8,557,741 for, 2 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 3,177,587 | 0 | 0 | 0 | For |
| Vanguard | 2,116,269 | 0 | 0 | 0 | For |
| BlackRock | 1,071,698 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 601,685 | 0 | 0 | 0 | For |
| Principal | 288,361 | 0 | 0 | 0 | For |
| Fidelity | 275,464 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 0 | 0 | 0 | For |
| Charles Schwab | 113,454 | 0 | 0 | 0 | For |
| Equitable | 95,008 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 78,858 | 0 | 0 | 0 | For |
| TIAA | 67,977 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,500 | 0 | 0 | 0 | For |
| Russell Investments | 52,939 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 50,205 | 0 | 0 | 0 | For |
| State Street | 41,674 | 2 | 0 | 0 | For |
| Northern Trust | 30,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 29,200 | 0 | 0 | 0 | For |
| ProShares | 19,863 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,236 | 0 | 0 | 0 | For |
| Global X | 19,029 | 0 | 0 | 0 | For |
| Dimensional | 17,431 | 0 | 0 | 0 | For |
| John Hancock | 14,574 | 0 | 0 | 0 | For |
| Invesco | 14,068 | 0 | 0 | 0 | For |
| Pacific Life | 11,918 | 0 | 0 | 0 | For |
| Nationwide | 11,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,215,472 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 7.35% |
| 2 | Vanguard | 4.90% |
| 3 | BlackRock | 2.48% |
| 4 | RBB FUND, INC. | 1.39% |
| 5 | Principal | 0.67% |
| 6 | Fidelity | 0.64% |
| 7 | BNY Mellon | 0.50% |
| 8 | Charles Schwab | 0.26% |
| 9 | Equitable | 0.22% |
| 10 | CARILLON SERIES TRUST | 0.18% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Venrock Adviser, LLC | 15.57% |
| 2 | MONTANOVA CAPITAL, LLC | 11.03% |
| 3 | Capital Group | 7.35% |
| 4 | Vestal Point Capital, LP | 3.00% |
| 5 | BlackRock | 2.89% |
| 6 | Octagon Capital Advisors LP | 2.47% |
| 7 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.20% |
| 8 | EMERALD MUTUAL FUND ADVISERS TRUST | 2.06% |
| 9 | EMERALD ADVISERS, LLC | 1.17% |
| 10 | DAFNA Capital Management LLC | 1.03% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Venrock Healthcare Capital Partners III, L.P. | 11.60% | DEF14A |
| Tang Capital Partners, LP | 11.44% | DEF14A |
| Entities affiliated with Frazier Life Sciences Public Fund, L.P. | 11.31% | DEF14A |
| Entities affiliated with Suvretta Capital Management, LLC | 10.02% | DEF14A |
| Vestal Point Capital, L.P. | 9.26% | DEF14A |
| BlackRock | 8.78% | 13F |
| Capital World Investors | 7.35% | DEF14A |
| Vanguard Group | 5.81% | 13F |
| Point72 | 4.94% | 13F |
| State Street | 4.53% | 13F |
Percentages above are of 43,215,472 shares outstanding, as reported by KalVista Pharmaceuticals, Inc. on its Form 10-Q dated August 26, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KalVista Pharmaceuticals, Inc.’s 10-Q dated August 26, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At KalVista Pharmaceuticals, Inc.'s shareholder meeting held October 1, 2025, in the 2025-2026 proxy season, 165 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 633 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation paid by us to our named… — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KalVista Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on October 2, 2025.
KalVista Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.